There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested.
- Eli Lilly: the trials and tribulations of antibody patents 17-04-2018
- AstraZeneca: no time for time-wasting 08-03-2018
- Getting into the biosimilars action 06-03-2018
- The licensing landscape at Pieris 22-02-2018
- A helping hand for rare diseases 08-02-2018
Latest americas news
Novartis has acquired clinical-stage gene therapy company AveXis.